Table 2 Comparison of baseline characteristics between patients with nephrotic syndrome and nephrotic-range proteinuria after matching in IgA nephropathy
Variables | NS group (n = 59) | NR group (n = 57) | P Value |
|---|---|---|---|
Age (y) | 42.69 ± 14.96 | 40.67 ± 11.33 | 0.413 |
Gender (M/F) | 26/33 | 28/29 | 0.585 |
SBP (mm Hg) | 124 ± 14 | 130 ± 23 | 0.434 |
HB (g/l) | 120.69 ± 24.73 | 134.9 ± 20.70 | 0.001 |
Scr (umol/l) | 127.34 ± 114.88 | 143.5 ± 86.09 | 0.393 |
eGFR (ml/min.1.73m2) | 68.52 ± 33.04 | 61.58 ± 28.77 | 0.231 |
Proteinuria (g/24 h, median, IQR) | 5160 (4100 ~ 6444) | 5040 (4275 ~ 5770) | 0.557 |
Uric acid (umol/L) | 400.52 ± 107.04 | 438.16 ± 105.07 | 0.062 |
Alb (g/l) | 24.81 ± 3.98 | 34.82 ± 1.16 | < 0.001 |
C3 (mg/dl) | 92.88 ± 27.70 | 95.49 ± 15.5 | 0.555 |
C4 (mg/dl) | 25.16 ± 8.98 | 25.83 ± 7.88 | 0.343 |
Urine RBC (/ul,median,IQR) | 84.78 (17.62 ~ 206.12) | 94.4 (44.12 ~ 206.12) | 0.324 |
TC (mmol/l) | 7.46 ± 2.93 | 5.73 ± 1.54 | 0.02 |
TG (mmol/l) | 2.83 ± 1.89 | 2.74 ± 1.52 | 0.824 |
LDL (mmol/l) | 4.45 ± 1.86 | 3.27 ± 1.16 | 0.02 |
Total IgA (mg/ml) | 295.62 ± 111.48 | 310.38 ± 124.33 | 0.536 |
Total IgG (mg/ml)) | 653.76 ± 224.83 | 894.70 ± 223.73 | < 0.001 |
D-dimer (ng/ml) | 817.94 ± 606.54 | 373.31 ± 274.8 | < 0.001 |
FIB (g/l) | 4.37 ± 1.42 | 3.65 ± 0.53 | 0.003 |
CRP (mg/dl) | 0.54 ± 0.57 | 0.32 ± 0.23 | 0.068 |
Steroid (treatment%) | 57 (96.6%) | 53 (93%) | 0.435 |
Immunosuppressor (treatment%) | 33 (55.9%) | 34 (59.6%) | 0.685 |
The RAS inhibitor (treatment%) | 31 (52.5%) | 27 (47.4%) | 0.401 |
Follow up time (months) | 31.53 ± 28.58 | 29.12 ± 26.66 | 0.641 |
Pathological findings | |||
M (M0/M1) | 5/54 | 2/55 | 0.262 |
E (E0/E1) | 14/45 | 29/28 | 0.002 |
S (S0/S1) | 14/45 | 5/52 | 0.03 |
T (T0/T1/T2) | 8/29/22 | 12/27/18 | 0.593 |
C (C0/C1/C2) | 8/20/31 | 11/29/17 | 0.046 |